CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.
ESG at Chugai Group
Chugai Group conducts its business activities to fulfill its mission of benefiting the medical community and human health around the world.
Browse through the latest news and developments by CPR and the Chugai Group.
- New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studies for the Combination Therapy with Multiple Tumor Types in Japan
- Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficiency Solution.